RESUMEN
BACKGROUND AND OBJECTIVES: The aim of this survey was to evaluate the knowledge about Patient Blood Management (PBM) principles and practices amongst clinicians working in seven European hospitals participating in a European Blood Alliance (EBA) project. MATERIALS AND METHODS: A web-based questionnaire was sent to 4952 clinicians working in medical, surgery and anaesthesiology disciplines. The responses were analysed, and the overall results as well as a comparison between hospitals are presented. RESULTS: A total of 788 responses (16%) were obtained. About 24% of respondents were not aware of a correlation between preoperative anaemia (POA) and perioperative morbidity and mortality. For 22%, treatment of POA was unlikely to favourably influence morbidity and mortality even before surgery with expected blood loss. More than half of clinicians did not routinely treat POA. 29%, when asked which is the best way to treat deficiency anaemia preoperatively, answered that they did not have sufficient knowledge and 5% chose to 'do nothing'. Amongst those who treated POA, 38% proposed red cell transfusion prior to surgery as treatment. Restrictive haemoglobin triggers for red blood cell transfusion, single unit policy and reduction of number and volumes of blood samples for diagnostic purposes were only marginally implemented. CONCLUSION: Overall, the responses indicated poor knowledge about PBM. Processes to diagnose and treat POA were not generally and homogeneously implemented. This survey should provide further impetus to implement programmes to improve knowledge and practice of PBM.
Asunto(s)
Anemia/terapia , Competencia Clínica , Complicaciones Posoperatorias/prevención & control , Anemia/complicaciones , Manejo de la Enfermedad , Transfusión de Eritrocitos/métodos , Europa (Continente) , Encuestas de Atención de la Salud , Hospitales Universitarios , Humanos , Complicaciones Posoperatorias/etiologíaRESUMEN
BACKGROUND AND OBJECTIVES: Treatment of dilutional coagulopathy by transfusing fresh frozen plasma (FFP) remains sub-optimal. We hypothesized that partial replacement of transfused FFP by fibrinogen concentrate results in improved coagulant activity and haemostasis. This was tested in a controlled clinical intervention trial with patients experiencing massive bleeding during major surgery. METHODS: Patients undergoing major elective surgery were treated according to current protocols. When transfusion with FFP was required, patients were randomized as follows: group A received 4 units FFP and group B received 2 units FFP plus 2 g fibrinogen concentrate. Blood samples were taken before and after the intervention. Analysts were blinded to the treatment type. RESULTS: Group A (B) consisted of 21 (22) patients, in 16 (17) of whom bleeding stopped after intervention. Plasma fibrinogen increased significantly more in group B (0·57 g/l) than in group A (0·05 g/l). However, levels of prothrombin and factors VIII, IX and X increased more in group A than in group B. Rotational thromboelastometry (ROTEM) of whole blood and plasma revealed improved fibrin clot formation in group B but not in group A. Thrombin generation [calibrated automated thrombogram (CAT)] in plasma increased more in group A. Principal parameters determining whole-blood thromboelastometry were the fibrinogen level and platelet count. In vitro addition of fibrinogen and prothrombin complex concentrate to pre-intervention samples restored both ROTEM and CAT parameters. CONCLUSIONS: Partial replacement of transfused FFP by fibrinogen increases fibrin clot formation at the expense of less improved thrombin generation. Coagulation factors other than fibrinogen alone are required for full restoration of haemostasis.
Asunto(s)
Trastornos de la Coagulación Sanguínea/terapia , Transfusión de Componentes Sanguíneos , Fibrinógeno/uso terapéutico , Procedimientos Quirúrgicos Operativos/efectos adversos , Procedimientos Quirúrgicos Operativos/métodos , Anciano , Trastornos de la Coagulación Sanguínea/sangre , Trastornos de la Coagulación Sanguínea/etiología , Factores de Coagulación Sanguínea/metabolismo , Pérdida de Sangre Quirúrgica/prevención & control , Femenino , Fibrina/efectos de los fármacos , Fibrina/metabolismo , Hemostasis/efectos de los fármacos , Humanos , Masculino , Persona de Mediana Edad , Plasma/metabolismo , Recuento de Plaquetas , Hemorragia Posoperatoria/prevención & control , Hemorragia Posoperatoria/terapia , Estudios Prospectivos , TromboelastografíaRESUMEN
Patients subjected to haemodilution during surgery are at increased risk of bleeding. We hypothesised that, in the acquired dilutional coagulopathy, insufficient haemostasis is due to either insufficient thrombin generation or insufficient fibrin clot formation. In tissue factor-activated plasmas from patients with coagulation deficiency, we measured time curves of thrombin generation and fibrin clot formation (thromboelastography). Investigated were in study A: 10 patients treated with vitamin K antagonist and five healthy subjects; in study B: 30 patients undergoing cardiopulmonary bypass (CPB) surgery and infused with on average 2,000 ml crystalloids and colloids (no major bleeding); in study C: 58 patients undergoing major general surgery, and transfused with >5,000 ml crystalloids, colloids and red cell concentrates, who experienced major bleeding and were post-transfused with fresh frozen plasma. The treatment with vitamin K antagonist led to a progressive reduction in thrombin generation but not fibrin clot formation. In CPB patients, plasma factor levels post-surgery were 53-60% of normal. This was accompanied by moderate reduction in both haemostatic processes. In plasmas from patients undergoing major surgery, factor levels were 38-41% of normal, and these levels increased after plasma transfusion. Taking preset thresholds for normal thrombin generation and fibrin clot formation, at least one of these processes was low in 88-93% of the patients with (persistent) bleeding, but only in 40-53% of the patients without bleeding. In conclusion, the ability of thrombin generation and fibrin clot formation is independently reduced in acquired dilutional coagulopathy, while minimal levels of both are required for adequate haemostasis.
Asunto(s)
Fibrina/metabolismo , Hemodilución , Hemorragia/etiología , Trombina/biosíntesis , Anciano , Coagulación Sanguínea , Trastornos de la Coagulación Sanguínea/etiología , Pérdida de Sangre Quirúrgica/prevención & control , Transfusión Sanguínea , Soluciones Cristaloides , Femenino , Hemorragia/prevención & control , Hemostasis , Humanos , Soluciones Isotónicas/uso terapéutico , Cinética , Masculino , Persona de Mediana Edad , Atención Perioperativa , Hemorragia Posoperatoria/etiología , Hemorragia Posoperatoria/terapia , Vitamina K/antagonistas & inhibidoresRESUMEN
Central venous catheters (CVCs) have considerably improved the management of patients with hematological malignancies, by facilitating chemotherapy, supportive therapy and blood sampling. Complications of insertion of CVCs include mechanical (arterial puncture, pneumothorax), thrombotic and infectious complications. CVC-related thrombosis and infections are frequently occurring complications and may cause significant morbidity in patients with hematological malignancies. CVC-related thrombosis and infections are related and can therefore not be seen as separate entities. The incidence of symptomatic CVC-related thrombosis had been reported to vary between 1.2 and 13.0% of patients with hematological malignancy. The incidence of CVC-related bloodstream infections varies between 0.0 and 20.8%. There is need for a specific approach regarding diagnosis and treatment of CVC-related thrombosis and infection with specific attention to the preservation of the catheter. Since data on CVC-related infections and thrombosis in hematological patients have been obtained mainly from retrospective studies of small sample size, prospective, randomized studies of prophylactic measures concerning CVC-related thrombosis and infection are warranted.
Asunto(s)
Infecciones Bacterianas/etiología , Cateterismo Venoso Central/efectos adversos , Neoplasias Hematológicas/terapia , Trombosis/etiología , Anticoagulantes/uso terapéutico , Bacteriemia/etiología , Bacteriemia/prevención & control , Infecciones Bacterianas/prevención & control , Humanos , Factores de Riesgo , Trombosis/prevención & controlRESUMEN
Abnormalities in blood coagulation are relatively common after traumatic brain injury (TBI) and play an important role in the morbidity and mortality after head injuries. Exposure oftissue factor, which is abundantly present in brain tissue, is the initiator of the coagulation cascade and plays an important role in the pathogenesis of coagulopathy after TBI. Coagulopathy after TBI is actually a manifestation of the disseminated intravascular coagulation (DIC) syndrome. The interplay between hypothermia, acidosis and progressive coagulopathy, referred to as the 'lethal triad', results in high mortality. This necessitates damage control in the treatment of such TBI patients. Repeated laboratory evaluation of the coagulation parameters in TBI patients is indicated, even if the initial values are normal. The DIC score, a combination of frequently used coagulation parameters, is not only a measure of the coagulopathy but can also predict the outcome and prognosis following TBI. Primary and secondary prevention of coagulopathy together with timely and effective intervention are the most important elements in the treatment of coagulation disorders. Nevertheless, the risk of death remains high.
Asunto(s)
Trastornos de la Coagulación Sanguínea/complicaciones , Coagulación Sanguínea , Lesiones Encefálicas/complicaciones , Trastornos de la Coagulación Sanguínea/tratamiento farmacológico , Trastornos de la Coagulación Sanguínea/epidemiología , Trastornos de la Coagulación Sanguínea/mortalidad , Lesiones Encefálicas/mortalidad , Coagulantes/uso terapéutico , Coagulación Intravascular Diseminada/complicaciones , Coagulación Intravascular Diseminada/tratamiento farmacológico , Coagulación Intravascular Diseminada/epidemiología , Coagulación Intravascular Diseminada/mortalidad , HumanosRESUMEN
BACKGROUND: Recombinant factor VIIa (rFVIIa), which was developed for treatment of inhibitor-complicated hemophilia, appears suitable as prohemostatic agent in other clinical disorders including patients with thrombocytopenia. It is generally accepted that rFVIIa functions by enhancement of thrombin generation at the site of injury. It is, however, unknown if and how this affects platelet adhesion and aggregation. OBJECTIVES: To determine the effect of rFVIIa-mediated thrombin generation on platelet adhesion and aggregation under flow conditions at normal and reduced platelet counts. METHODS: Washed platelets and red cells were combined to obtain plasma-free blood with different platelet counts. The reconstituted blood was perfused over a collagen- or fibrinogen-coated surface in the absence or presence of a thrombin generating system consisting of purified coagulation factors rFVIIa, factor (F)X and prothrombin. RESULTS: Addition of coagulation factors rFVIIa, FX and prothrombin to washed platelets and red cells enhanced platelet adhesion and aggregation to collagen and adhesion and spreading to fibrinogen at normal platelet count and at platelet numbers as low as 10 000 microL(-1). rFVIIa-mediated thrombin generation enhanced the activation state of platelets as measured by intracellular calcium fluxes, and enhanced the exposure of procoagulant phospholipids as measured by annexin A5 binding. CONCLUSIONS: Taken together, increased platelet adhesion and aggregation by rFVIIa-mediated thrombin formation may explain the therapeutic effects of rFVIIa in thrombocytopenic conditions and in patients with a normal platelet count by (i) enhancement of primary hemostasis and (ii) enhancement of procoagulant surface leading to elevated fibrin formation.
Asunto(s)
Factor VII/farmacología , Adhesividad Plaquetaria/efectos de los fármacos , Proteínas Recombinantes/farmacología , Anexina A5/química , Plaquetas/metabolismo , Calcio/metabolismo , Colágeno/química , Colágeno/metabolismo , Relación Dosis-Respuesta a Droga , Factor VIIa , Factor X/química , Fibrinógeno/metabolismo , Hemostasis , Humanos , Microscopía Fluorescente , Perfusión , Fosfatidilserinas/química , Fosfolípidos/metabolismo , Recuento de Plaquetas , Unión Proteica , Protrombina/metabolismo , Transducción de Señal , Trombina/metabolismo , Trombocitopenia/tratamiento farmacológico , Trombocitopenia/metabolismo , Trombosis/metabolismo , Factores de TiempoRESUMEN
Elevated levels of coagulation factor VIII:C (FVIII:C) are associated with an increased risk for venous and arterial thromboembolism. Whether relatives of patients with elevated levels of FVIII:C are also at increased risk for thrombotic disease is unknown. The objective was to determine the annual incidences of both venous and arterial thrombotic events in first-degree relatives of patients with elevated levels of FVIII:C and venous thromboembolism (VTE) or premature atherosclerosis. A retrospective study with 584 first-degree relatives of 177 patients with elevated levels of FVIII:C was performed. The level of FVIII:C was determined and relatives with elevated and normal levels of FVIII:C were compared. Of the participants, 40% had elevated levels of FVIII:C. The annual incidence of a first episode of VTE was 0.34% and 0.13% in relatives with elevated levels of FVIII:C and those with normal levels, respectively [OR 3.7 (95% CI 1.9-7.5)]. The absolute annual incidence in the youngest age group with elevated levels of FVIII:C was 0.16% (0.05-0.37) and gradually increased to 0.99% (0.40-2.04) in those older than 60 years of age, although the odds ratios were not statistically significant. The annual incidences of a first arterial thrombotic event were 0.29% and 0.14% in relatives with and without elevated levels of FVIII:C, respectively [OR 3.1 (1.4-6.6)]. In particular the risks for a first myocardial infarction [OR 4.3 (1.0-18.1); P =0.046] and a first peripheral arterial thrombosis [OR 8.6 (1.6-47.6)] were increased. Within families of patients with elevated levels of FVIII:C and VTE or premature atherosclerosis, 40% of their first-degree relatives has elevated levels of FVIII:C as well, and they are at increased risk for both VTE and arterial thrombosis as compared with their relatives with normal levels.
Asunto(s)
Factor VIII/biosíntesis , Tromboembolia/sangre , Trombosis de la Vena/sangre , Adolescente , Adulto , Factores de Edad , Anciano , Arteriosclerosis , Salud de la Familia , Femenino , Humanos , Masculino , Persona de Mediana Edad , Infarto del Miocardio/sangre , Infarto del Miocardio/complicaciones , Oportunidad Relativa , Embarazo , Estudios Retrospectivos , Riesgo , Factores de Riesgo , Tromboembolia/etiología , Trombosis de la Vena/etiologíaAsunto(s)
Anticuerpos Antifosfolípidos/inmunología , Síndrome Antifosfolípido/diagnóstico , Síndrome Antifosfolípido/inmunología , Adulto , Anticuerpos Anticardiolipina/análisis , Anticuerpos Anticardiolipina/inmunología , Anticuerpos Antifosfolípidos/análisis , Diagnóstico Diferencial , Ensayo de Inmunoadsorción Enzimática , Femenino , Glicoproteínas/inmunología , Humanos , Lupus Eritematoso Sistémico , Masculino , Tamizaje Masivo/métodos , Persona de Mediana Edad , Estudios Retrospectivos , Medición de Riesgo , Muestreo , beta 2 Glicoproteína IRESUMEN
Elevated levels of soluble uPAR (s-uPAR) and other fibrinolytic parameters functionally related to the urokinase-type plasminogen activator system might indicate the presence of cancer cells. In 25 breast cancer patients with metastases s-uPAR was significantly increased compared with 25 patients without metastases and with 25 healthy controls: 420 pg mL-1 vs. 145 pg mL-1 (P = 0.005) and 190 pg mL-1 (P = 0.003). Plasmin-alpha2-antiplasmin (PAP) complexes and d-dimers were significantly increased in breast cancer patients with metastases compared with patients without metastases and with healthy controls. The levels of plasminogen activator inhibitor (PAI)-1 activity, uPA antigen and factor (F)XIIa did not significantly differ between the patient groups and healthy controls. PAP complexes (529 microg L-1 vs. 420 microg L-1; P = 0.03), d-dimers (278.5 ng mL-1 vs. 79.0 ng mL-1; P = 0.005) and FXIIa (1.64 ng mL-1 vs. 1.19 ng mL-1; P = 0.01) were significantly higher in patients with metastases not surviving compared with patients with metastases surviving the 3-year follow-up period. Plasma s-uPAR levels in the patients with metastases did not discriminate between patients surviving and patients not surviving after 3-year follow-up. No significant differences in s-uPAR or any of the other parameters were found in the five patients developing metastases during follow-up. A single value of s-uPAR is of limited value in the follow-up of breast cancer patients with and without metastatic disease and does not predict survival or future metastases.
Asunto(s)
Neoplasias de la Mama/patología , Metástasis de la Neoplasia/diagnóstico , Receptores de Superficie Celular/sangre , Anciano , Biomarcadores/sangre , Factores de Coagulación Sanguínea/análisis , Neoplasias de la Mama/sangre , Neoplasias de la Mama/mortalidad , Estudios de Casos y Controles , Femenino , Estudios de Seguimiento , Humanos , Persona de Mediana Edad , Valor Predictivo de las Pruebas , Pronóstico , Receptores del Activador de Plasminógeno Tipo Uroquinasa , Solubilidad , Tasa de SupervivenciaRESUMEN
BACKGROUND AND OBJECTIVES: In this study we examined whether prestorage leucocyte reduction prevents the accumulation of bioreactive substances in red cell units. MATERIALS AND METHODS: Measurements were performed in the supernatants of buffy-coat-depleted (standard red cells) and leucocyte-reduced (filtered red cells) red cell units. The effect of storage was evaluated by taking repetitive samples up to 35 days after donation. We determined the concentrations of polymorphonuclear neutrophil (PMN)-derived bactericidal permeability increasing protein (BPI), defensins and annexin A5. In addition, leucocyte counts (using nageotte chamber) were performed on days 0 and 35. RESULTS: During storage, the concentrations of BPI, defensins and annexin A5 in standard red cells gradually increased. However, in the filtered red cells BPI and defensins were found in only a few samples, whereas the annexin A5 concentration in these units did not change during storage. Haemolysis data in both types of red cell components were similar at all time-points, except prestorage. Significant correlations were found between the release of BPI, defensins and annexin A5 into red cell units and the loss of leucocytes during storage. CONCLUSIONS: PMNs lose their membrane integrity during cold storage and release their contents into red cell components. Prestorage leucocyte reduction of red cell components prevents the accumulation of BPI, defensins and annexin A5.